Moderna Inc. (MRNA) said it entered into a collaboration with Catalent (CTLT) for large-scale, commercial manufacturing of its mRNA-based experimental vaccine candidate against the novel coronavirus.As part of the agreement, Catalent will provide vial filling and packaging, as well as additional staffing at its facility for the production of an initial 100 million doses of the vaccine candidate to supply the U.S. market starting in the third quarter of this year. The companies said that they are also in talks to secure capacity for continued production of hundreds of millions of additional doses.The announcement pushed Catalent shares up 3.2% to …read more
Source:: Yahoo Finance
